TBPH

Theravance Biopharma

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$407.3M

Burn Rate (Qtr)

-$73.6M

Company Profile

Theravance Biopharma, Inc. ("Theravance Biopharma") is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Our research is focused in the areas of inflammation and immunology.

In pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk.

These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution. Our pipeline of internally discovered programs is targeted to address significant patient needs.

We have an economic interest in potential future payments from Glaxo Group or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY ELLIPTA.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

YUPELRI® (revefenacin)

Chronic obstructive pulmonary disease (COPD)

Quarterly Sales (Approved)

February 26, 2021 (Est)

TRELEGY ELLIPTA

Chronic obstructive pulmonary disease (COPD)

Quarterly Sales (Approved)

February 26, 2021 (Est)

TRELEGY ELLIPTA

Asthma

Quarterly Sales (Approved)

February 26, 2021 (Est)

AMPRELOXETINE (TD-9855)

Neurogenic orthostatic hypotension (nOH)

Phase 3

Q3 2021

TD-8236 (LUNG-SELECTIVE JAK INHIBITOR)

Inflammatory lung diseases

Phase 2

TD-0903 (LUNG-SELECTIVE JAK INHIBITOR)

Inflammatory lung diseases

Phase 2

TD-0903 (Janus kinase inhibitor (JAKi))

COVID-19

Phase 2 (Top-line Data)

Q2 2021

TD-1473 (GUT-SELECTIVE JAK INHIBITOR)

Crohn's disease

Phase 2

Q3 2021

TD-1473 (GUT-SELECTIVE JAK INHIBITOR)

Ulcerative colitis

Phase 2b/3 (Top-line Data)

Q3 2021

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon